CTOs on the Move

Mobilion Systems

www.mobilionsystems.com

 
MOBILion Systems is enabling advancements in disease diagnosis and treatment by commercializing instruments that improve multi-omics disease, drug, and biomarker discovery.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Mobilion Systems raised $15.4M on 11/12/2019
Mobilion Systems raised $35M on 08/17/2020

Similar Companies

Medallion Laboratories

Medallion Laboratories is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Escient Pharmaceuticals

Based in San Diego, we are led by an experienced team of entrepreneurs with deep roots in this region`s life sciences ecosystem and specific expertise in GPCR drug discovery and development. Escient Pharmaceuticals is supported by top-tier life-sciences investors with a proven track record for identifying and supporting successful, next-generation medicines companies.

Lynxcom Partners

Lynxcom Partners is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arvinas

Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets.

Gotham Therapeutics

Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins.